NCT07516678Recruiting
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
A Prospective Observational Study of Serial Circulating Tumor DNA and Molecular Residual Disease Monitoring for Molecular Profiling, Treatment Response Assessment, and Early Relapse Detection in Patients With Neuroblastoma
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma. The study aims to characterize baseline genomic alterations, assess ctDNA detectability and dynamic changes during treatment and follow-up, compare tumor-informed personalized MRD assays with fixed-panel assays, and determine the clinical utility of ctDNA/MRD for treatment response assessment, molecular remission evaluation, relapse surveillance, and early detection of disease progression.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 1 Apr 2026
- Start date
- 1 Jan 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT07516678
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Inability to provide protocol-required blood samples for ctDNA/MRD testing. Insufficient clinical information for protocol-defined response or outcome analyses.
- Poor-quality or insufficient biospecimens that preclude molecular analysis, when molecular testing is a required component of the study dataset.
- Any condition that, in the opinion of the investigator, would make study participation inappropriate.
Who the study is looking for
- Patients with histologically or clinically confirmed neuroblastoma according to institutional or protocol-defined diagnostic criteria.
- Newly diagnosed, relapsed, refractory, or progressive neuroblastoma eligible for serial biospecimen collection during routine clinical care.
- Availability of peripheral blood samples for ctDNA/MRD analysis at baseline and/or longitudinal follow-up time points.
- Availability of clinical data required for molecular-clinical correlation analyses, including response and outcome assessment.
- Availability of tumor tissue and matched control samples for tumor-informed assay development, if applicable and feasible.
- Written informed consent from a parent or legal guardian, and assent from the participant when applicable.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.